The State of HCP Engagement 2026: Data vs. Hype Report
December 3, 2025
The State of HCP Engagement 2026: Separating Vendor Hype from Commercial Reality
- March 12, 2026
Sales, marketing, and commercial execution
The State of HCP Engagement 2026: Separating Vendor Hype from Commercial Reality
The pharma field sees launches as key. Launches set brand paths. A
In today’s healthcare scene, pharma firms work with many groups. Each group
In today’s fast pharma scene, brands act. Customer talk must hit, feel
In recent years, the mounting pressure to lower drug prices has prompted
Eli Lilly has cemented its place in pharmaceutical history by reaching an
As we navigate a world emerging from the pandemic, few companies exemplify
In a world grappling with the aftermath of a pandemic, Moderna has
Pfizer’s recent acquisition of Metsera marks a crucial step in the pharmaceutical
Redemplo (plozasiran) cleared for familial chylomicronemia syndrome at $60,000 annual price—ten times
The recent announcement from the White House about a new trade deal,
In a bold move that signals its commitment to advancing cancer treatment,
The landscape of drug pricing in the United States is at a
Moderna, a prominent name in the biopharmaceutical landscape best known for its
Eli Lilly has made waves in the pharmaceutical industry with its groundbreaking
In the world of biopharmaceuticals, where innovation meets investment, quarterly earnings reports
In the ever-evolving biopharmaceutical landscape, Eli Lilly has taken center stage with
BioMarin Pharmaceutical has recently announced a significant development regarding its gene therapy,
The biopharmaceutical industry is continually evolving, with innovative therapies emerging to transform
In a surprising turn of events, Kevin Ali, the CEO of Organon,
